Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>Altimmune presented its fourth quarter and full-year 2024 financial results, focusing on significant milestones and upcoming developments.</li>
<li>The company has made strides in its clinical programs, especially its lead candidate, pemvidutide, intended for the treatment of non-alcoholic steatohepatitis (NASH), alongside addressing obesity and other potential indications.</li>
<li>On the clinical front, Altimmune has advanced its IMPACT trial, a Phase IIb study of pemvidutide in NASH, which aims to demonstrate NASH resolution and fibrosis improvement after a 24-week treatment period.</li>
</ul>


Altimmune presented its fourth quarter and full-year 2024 financial results, focusing on significant milestones and upcoming developments.
The company has made strides in its clinical programs, especially its lead candidate, pemvidutide, intended for the treatment of non-alcoholic steatohepatitis (NASH), alongside addressing obesity and other potential indications.
On the clinical front, Altimmune has advanced its IMPACT trial, a Phase IIb study of pemvidutide in NASH, which aims to demonstrate NASH resolution and fibrosis improvement after a 24-week treatment period.


Altimmune’s Strategic Moves Spark M&A Buzz: Is It The Hottest Player In Obesity & Liver Disease?

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>In a week of bad industry news, biopharma surprisingly held onto its bounce from recent two-year lows.</li><li>With pharma tariffs now expected by June and federal health agencies’ prospects looking worse, we may be close to peak negativity, but too much uncertainty remains for any confidence in a bottom.</li><li>In obesity, LLY had a win for an oral GLP-1, while PFE lost, affecting NVO, GPCR, VKTX, AMGN, MTSR, ALT, and TERN. VERV gained on CVD data and BMY’s heart drug failed, affecting CYTK and EWTX, while MURA stopped development.</li></ul>

In a week of bad industry news, biopharma surprisingly held onto its bounce from recent two-year lows.With pharma tariffs now expected by June and federal health agencies’ prospects looking worse, we may be close to peak negativity, but too much uncertainty remains for any confidence in a bottom.In obesity, LLY had a win for an oral GLP-1, while PFE lost, affecting NVO, GPCR, VKTX, AMGN, MTSR, ALT, and TERN. VERV gained on CVD data and BMY’s heart drug failed, affecting CYTK and EWTX, while MURA stopped development.

Biopharma Week in Review Shrugging Off Constant Bad News; LLY Winning Obesity Drug Race

United States

Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of novel peptide-based therapeutics for the treatment of obesity, NASH, chronic hepatitis B, and liver diseases. Altimmune serves patients and healthcare professionals worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Altimmune (ALT US)

Altimmune’s Strategic Moves Spark M&A Buzz: Is It The Hottest Player In Obesity & Liver Disease?

Altimmune presented its fourth quarter and full-year 2024 financial results, focusing on significant milestones and upcoming developments.

Baptista Research

Biopharma Week in Review Shrugging Off Constant Bad News; LLY Winning Obesity Drug Race

With pharma tariffs now expected by June and federal health agencies’ prospects looking worse, we may be close to peak negativity, but too much...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)